Replies to post #122376 on Biotech Values

[jq1234]

Can you think of any market for the PH20+regular insulin?

I think HALO was trying to have broad development plan to demonstrate that PH20 can be added to both regular insulin and fast acting analog insulin. Your question about whether the PH20 in addition to regular insulin has as much market potential as PH20 in addition to fast acting insulin analog is valid. To me, it is worth the effort to confirm the utility for both in phase I and II because the extra cost isn't that much. Analog insulin still costs a lot more today, which might make PH20 have some market potential in developing countries for example. However, I don't know if it still does once fast acting insulin analog becomes generic.